How do I find recruiting Hepatocellular Carcinoma clinical trials?

Browse the actively recruiting Hepatocellular Carcinoma studies listed on this page, or take an assessment to see trials you may qualify for based on your profile.

Are Hepatocellular Carcinoma clinical trials free to join?

Costs, travel support, and any payment for taking part vary by study. Ask the study team what is covered before you decide to join.

Who can take part in a Hepatocellular Carcinoma clinical trial?

Each study has its own eligibility criteria (for example age, disease stage, and prior treatments). This page is general information and not medical advice; discuss any specific trial with your healthcare provider to confirm whether it is appropriate for you.

Hepatocellular Carcinoma Clinical Trials

Hepatocellular Carcinoma clinical trials evaluate new drugs, immunotherapies, radiation approaches, and combination treatments for hepatocellular Carcinoma. Corterve aggregates actively recruiting Hepatocellular Carcinoma studies from the public ClinicalTrials.gov registry so you can browse them by location and eligibility. Many oncology trials enroll patients at different stages of disease, including newly diagnosed and previously treated. This is general information, not medical advice — review any study with your oncology care team before enrolling.

Browse all Hepatocellular Carcinoma trials Take the assessment

Recruiting Hepatocellular Carcinoma studies

Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.
NCT07227012PHASE1, PHASE2PfizerCarcinoma, HepatocellularIrvine, California
Impact of "Teaching the Teachers" Concept on Global Education and Application of Hepatocellular Carcinoma Diagnosis Guidelines
NCT05143619M.D. Anderson Cancer CenterHepatocellular CarcinomaHouston, Texas
A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
NCT06066138PHASE1National Cancer Institute (NCI)Locally Advanced Alveolar Soft Part SarcomaBethesda, Maryland
A Study of ZW251 in Participants With Advanced Solid Tumors
NCT07164313PHASE1Zymeworks BC Inc.Hepatocellular CarcinomaSan Francisco, California
Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer
NCT03942328PHASE1, PHASE2Mayo ClinicStage III Hepatocellular Carcinoma AJCC v8Rochester, Minnesota
Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
NCT06265285PHASE2Mayo ClinicAdvanced Esophageal Squamous Cell CarcinomaJacksonville, Florida
A Phase 1 Study of the Safety and Tolerability of CTX-10726
NCT07419841PHASE1Compass TherapeuticsGastroesophageal Cancer (GC)Phoenix, Arizona
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
NCT05176483PHASE1ExelixisRenal Cell Carcinoma (RCC)Phoenix, Arizona
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
NCT07285044PHASE2Mayo ClinicAmyloidosisJacksonville, Florida
Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC
NCT06726161PHASE1, PHASE2RayzeBio, Inc.Hepatocellular Carcinoma (HCC)Birmingham, Alabama
Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure
NCT07219459PHASE2CatalYm GmbHUnresectable or Metastatic Hepatocellular CarcinomaIrvine, California
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
NCT07291076PHASE1, PHASE2Bristol-Myers SquibbHepatocellular Carcinoma (HCC)Duarte, California

See all 110 recruiting trials →

Hepatocellular Carcinoma trials by state

Hepatocellular Carcinoma trials by metro

Frequently asked questions

How do I find recruiting Hepatocellular Carcinoma clinical trials?: Browse the actively recruiting Hepatocellular Carcinoma studies listed on this page, or take an assessment to see trials you may qualify for based on your profile.
Are Hepatocellular Carcinoma clinical trials free to join?: Costs, travel support, and any payment for taking part vary by study. Ask the study team what is covered before you decide to join.
Who can take part in a Hepatocellular Carcinoma clinical trial?: Each study has its own eligibility criteria (for example age, disease stage, and prior treatments). This page is general information and not medical advice; discuss any specific trial with your healthcare provider to confirm whether it is appropriate for you.